Abstract
Introduction: Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that, in severe forms, may lead to respiratory failure, autonomic dysfunction, and long-term disability. Plasma exchange (PE) and intravenous immunoglobulin (IVIg) are standard immunomodulatory therapies; however, questions remain regarding their comparative performance and feasibility across healthcare settings. Objective: To synthesize recent scientific evidence on the efficacy, safety, and clinical applicability of plasma exchange versus IVIg in severe GBS. Methodology: A qualitative documentary and analytical review (2022–2026) were conducted using PubMed, Scopus, Web of Science, and Cochrane Library databases. Systematic reviews, meta-analyses, observational studies, and clinical reviews were included. Findings were organized into comparative matrices and critically interpreted. Results: Current evidence indicates comparable overall efficacy between PE and IVIg in key outcomes, including clinical improvement, duration of mechanical ventilation, and length of hospital stay. Contextual differences were identified: IVIg is easier to administer and generally better tolerated, whereas PE may be more cost-effective in certain settings and remains a viable option in resource-limited environments. Early treatment initiation, particularly with IVIg, is associated with improved functional recovery. Conclusions: No consistent therapeutic superiority is observed. Treatment selection should be individualized according to disease severity, timing of intervention, patient risk profile, and institutional resources.

This publication has 11 references indexed in Scilit: